NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.82 -0.13 (-1.87 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$6.82
Today's Range$6.70 - $6.99
52-Week Range$5.60 - $11.93
Volume113,684 shs
Average Volume395,861 shs
Market Capitalization$255.38 million
P/E Ratio22.00
Dividend YieldN/A
Beta1.73
Avadel Pharmaceuticals logoAvadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVDL
CUSIPN/A
Phone636-449-1830

Debt

Debt-to-Equity Ratio1.28
Current Ratio2.66
Quick Ratio2.59

Price-To-Earnings

Trailing P/E Ratio22.00
Forward P/E Ratio-4.40
P/E GrowthN/A

Sales & Book Value

Annual Sales$172.74 million
Price / Sales1.45
Cash Flow$0.4394 per share
Price / Cash15.52
Book Value$2.18 per share
Price / Book3.13

Profitability

EPS (Most Recent Fiscal Year)$0.31
Net Income$68.27 million
Net Margins18.96%
Return on Equity-13.95%
Return on Assets-4.22%

Miscellaneous

Employees180
Outstanding Shares36,740,000
Market Cap$255.38

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How will Avadel Pharmaceuticals' stock buyback program work?

Avadel Pharmaceuticals announced that its board has approved a share buyback plan on Wednesday, March 28th 2018, which allows the company to repurchase $7,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 2.7% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's management believes its shares are undervalued.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its quarterly earnings results on Wednesday, May, 2nd. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.08. The business had revenue of $33.29 million for the quarter, compared to analyst estimates of $29.60 million. Avadel Pharmaceuticals had a negative return on equity of 13.95% and a net margin of 18.96%. View Avadel Pharmaceuticals' Earnings History.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Avadel Pharmaceuticals.

What price target have analysts set for AVDL?

3 brokerages have issued 1-year price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $22.6667 in the next twelve months. This suggests a possible upside of 232.4% from the stock's current price. View Analyst Ratings for Avadel Pharmaceuticals.

What is the consensus analysts' recommendation for Avadel Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a decline in short interest in the month of June. As of June 29th, there was short interest totalling 2,282,363 shares, a decline of 31.1% from the June 15th total of 3,310,728 shares. Based on an average trading volume of 561,837 shares, the days-to-cover ratio is currently 4.1 days. View Avadel Pharmaceuticals' Current Options Chain.

Who are some of Avadel Pharmaceuticals' key competitors?

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael S. Anderson, CEO & Director (Age 69)
  • Mr. Michael F. Kanan, Sr. VP & CFO (Age 55)
  • Mr. Gregory J. Divis, Exec. VP & COO (Age 53)
  • Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
  • Dr. David Monteith, VP of R&D (Age 54)

Has Avadel Pharmaceuticals been receiving favorable news coverage?

Media headlines about AVDL stock have been trending somewhat positive on Saturday, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Avadel Pharmaceuticals earned a media sentiment score of 0.11 on Accern's scale. They also gave news articles about the company an impact score of 45.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $6.82.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $255.38 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]


MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.